Back to Search
Start Over
Lupus anticoagulant associates with thrombosis in patients with COVID-19 admitted to intensive care units
- Source :
- Research and practice in thrombosis and haemostasis, 6(6):12809. Wiley, Research and Practice in Thrombosis and Haemostasis, 6(6):e12809. Wiley-Blackwell Publishing Ltd, Research and Practice in Thrombosis and Haemostasis, 6, 6, Research and Practice in Thrombosis and Haemostasis, 6, Research and practice in thrombosis and haemostasis, 6(6):e12809. Wiley-Blackwell Publishing Ltd, Research and Practice in Thrombosis and Haemostasis, 6(6). WILEY, Noordermeer, T, Schutgens, R E G, Visser, C, Rademaker, E, de Maat, M P M, Jansen, A J G, Limper, M, Cremer, O L, Kruip, M J H A, Endeman, H, Maas, C, de Laat, B, Urbanus, R T, the Dutch COVID & Thrombosis Coalition (DCTC), van de Beek, D, Brouwer, M C, de Bruin, S, Coppens, M, van Es, N, van Haaps, T F, Juffermans, N P, Muller, M C A, Vlaar, A P J, Hertogh, C M P M, Heunks, L M A, Hugtenburg, J G, van Kooten, J, Nossent, E J, Smulders, Y, Tuinman, P R, Noordegraaf, A V, Grootenboers, M J J H, van Guldener, C, Kant, M, Lansbergen, A, Faber, J, Hajer, G, Stemerdink, A, van den Akker, J, Bierings, R, Endeman, H, Goeijenbier, M, Hunfeld, N G M, van Gorp, E C M, Gommers, D A M P J, Koopmans, M P G, Kruip, M J H A, Kuiken, T, Langerak, T, Leebeek, Lauw, M N, de Maat, M P M, Noack, D, Paats, M S, Raadsen, M P, Rockx, B, Rokx, C, Schurink, C A M, Tong-Minh, K, van den Toorn, L, den Uil, C A, Visser, C, Boutkourt, F, Roest, T, Douma, R A, de Haan, L R, ten Wolde, M, Bemelmans, R H H, Festen, B, Stads, S, de Jager, C P C, Simons, K S, Antoni, M L, Bos, M H, Burggraaf, J L I, Cannegieter, S C, Eikenboom, H C J, den Exter, P L, Geelhoed, J J M, Huisman, M V, de Jonge, E, Kaptein, F H J, Klok, F A, Kroft, L J M, Lijfering, W M, Nab, L, Ninaber, M K, Putter, H, Ramai, S R S, da Rocha Rondon, A M, Roukens, A H E, Stals, M A M, Versteeg, H H, Vliegen, H W, van Vlijmen, B J M, van de Berg, T, Bruggemann, R, van Bussel, B C T, ten Cate, H, ten Cate-Hoek, A, Hackeng, T M, Henskens, I Y, Hulshof, A, Mulder, M, Olie, R H, Schurgers, L, Spaetgens, B, Spronk, H, Spruit, M A, Winckers, K, Nieuwenhuizen, L, Franken, B, Schrover, I M, de Waal, E G M, Beishuizen, A, Cornet, A, Krabbe, J, Kramers, K, Leentjens, J, de Mast, Q, Middeldorp, S, Brouwer, R E, Ellerbroek, J L J, Tijmensen, J, Hovens, M M C, Oostdijk, E A N, Westerhof, B D, Faber, L M, van den Biggelaar, M, Meijers, J C M, Voorberg, J, Kevenaar, M E, Soei, Y L, Wils, E J, Croles, F N, de Laat, B, Kamphuisen, P W, Vink, R, Lisman, T, Meijer, K, van Tichelaar, Y I G, Cremer, O L, Geersing, G, Kaasjager, H A H, Kusadasi, N, Huisman, A, Maas, C, Nijkeuter, M, Schutgens, R E G, Creveldkliniek, V, Urbanus, R T, Creveldkliniek, V, Westerink, J, Faber, H J, Koster, S C E, van Montfort, P & van Twist, D J L 2022, ' Lupus anticoagulant associates with thrombosis in patients with COVID-19 admitted to intensive care units : A retrospective cohort study ', Research and practice in thrombosis and haemostasis, vol. 6, no. 6, e12809 . https://doi.org/10.1002/rth2.12809
- Publication Year :
- 2022
-
Abstract
- Contains fulltext : 286889.pdf (Publisher’s version ) (Open Access) BACKGROUND: Thrombosis is a frequent and severe complication in patients with coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU). Lupus anticoagulant (LA) is a strong acquired risk factor for thrombosis in various diseases and is frequently observed in patients with COVID-19. Whether LA is associated with thrombosis in patients with severe COVID-19 is currently unclear. OBJECTIVE: To investigate if LA is associated with thrombosis in critically ill patients with COVID-19. PATIENTS/METHODS: The presence of LA and other antiphospholipid antibodies was assessed in patients with COVID-19 admitted to the ICU. LA was determined with dilute Russell's viper venom time (dRVVT) and LA-sensitive activated partial thromboplastin time (aPTT) reagents. RESULTS: Of 169 patients with COVID-19, 116 (69%) tested positive for at least one antiphospholipid antibody upon admission to the ICU. Forty (24%) patients tested positive for LA; of whom 29 (17%) tested positive with a dRVVT, 19 (11%) tested positive with an LA-sensitive aPTT, and 8 (5%) tested positive on both tests. Fifty-eight (34%) patients developed thrombosis after ICU admission. The odds ratio (OR) for thrombosis in patients with LA based on a dRVVT was 2.5 (95% confidence interval [CI], 1.1-5.7), which increased to 4.5 (95% CI, 1.4-14.3) in patients at or below the median age in this study (64 years). LA positivity based on a dRVVT or LA-sensitive aPTT was only associated with thrombosis in patients aged less than 65 years (OR, 3.8; 95% CI, 1.3-11.4) and disappeared after adjustment for C-reactive protein. CONCLUSION: Lupus anticoagulant on admission is strongly associated with thrombosis in critically ill patients with COVID-19, especially in patients aged less than 65 years.
- Subjects :
- lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]
lupus anticoagulant
risk factor
critically ill
Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]
lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]
COVID-19
Hematology
thrombosis
Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]
Subjects
Details
- Language :
- English
- ISSN :
- 24750379
- Volume :
- 6
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Research and practice in thrombosis and haemostasis
- Accession number :
- edsair.doi.dedup.....e56496ac798d2c415249e255bcb1695f